Genelux GNLX
NASDAQ GNLX
$2.72 -0.02 (-0.73%)
At close: Aug 21, 2026 · 4:00 PM EDT

Genelux (GNLX) Cash from Financing Activities (2022 - 2026)

Genelux (GNLX) posted quarterly Cash from Financing Activities of $18.5 million for Q1 2026, up 93.77% year-over-year from $9.6 million in Q1 2025, and up 6616.67% quarter-over-quarter from $276000.0 in Q4 2025.

Genelux (GNLX) Cash from Financing Activities (2022 - 2026) Analysis & Trends

Genelux's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $18.5 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities rose 93.77% year-over-year to $18.5 million; the TTM figure through Mar 2026 stood at $18.9 million (down 49.54% YoY), while the FY2025 annual figure was $9.9 million, down 65.29% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $18.5 million, up from $276000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $27.7 million in Q2 2024, with the low at -$130000.0 in Q1 2022.
  • The 5-year median for Cash from Financing Activities is $688000.0 (2024), against an average of $7.8 million.
  • The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities jumped 11361.54% in 2023, then tumbled 99.81% in 2025.
  • Genelux's Cash from Financing Activities stood at $545000.0 in 2022, then fell by 26.42% to $401000.0 in 2023, then plunged by 77.31% to $91000.0 in 2024, then jumped by 203.3% to $276000.0 in 2025, then surged by 6616.67% to $18.5 million in 2026.
  • Business Quant data shows GNLX's Cash from Financing Activities at $18.5 million in Q1 2026, $276000.0 in Q4 2025, and $52000.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 14.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -6.05 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 36.24 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -16.65 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 27.18 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -273.15 Mn
10 Genelux 119.87 Mn 119.87 Mn - 18.54 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 18.54 Mn
Mar 31, 2026 18.54 Mn
Dec 31, 2025 276,000.00
Dec 31, 2025 276,000.00
Jun 30, 2025 52,000.00
Jun 30, 2025 52,000.00
Mar 31, 2025 9.57 Mn
Mar 31, 2025 9.57 Mn
Dec 31, 2024 91,000.00
Dec 31, 2024 91,000.00
Jun 30, 2024 27.73 Mn
Jun 30, 2024 27.73 Mn
Mar 31, 2024 688,000.00
Mar 31, 2024 688,000.00
Dec 31, 2023 401,000.00
Dec 31, 2023 401,000.00
Sep 30, 2023 6.36 Mn
Sep 30, 2023 6.36 Mn
Jun 30, 2023 22.62 Mn
Jun 30, 2023 22.62 Mn